{"data":{"id":610,"lang":"en","title":"Johns Hopkins AI Blood Test Detects Silent Liver Disease Years Before Symptoms Appear","summary":"Johns Hopkins researchers created an AI blood test that detects early liver fibrosis and cirrhosis by analyzing DNA fragmentation patterns, outperforming current diagnostics.","category":"science","category_label":"Science","published_at":"2026-03-06T16:01:58Z","updated_at":"2026-03-06T16:01:58Z","url":"https://techtools.cz/tools/news/article/610-johns-hopkins-ai-blood-test-detects-silent-liver-disease-years-before-symptoms","api_url":"https://techtools.cz/news-api/v1/articles/610?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/610.md?lang=en","image_url":"https://scx1.b-cdn.net/csz/news/800a/2019/dna.jpg","word_count":169,"reading_time_minutes":1,"sources":[{"url":"https://medicalxpress.com/news/2026-03-ai-based-liquid-biopsy-liver.html","domain":"medicalxpress.com"},{"url":"https://www.sciencedaily.com/releases/2026/03/260305223204.htm","domain":"sciencedaily.com"},{"url":"https://www.news-medical.net/news/20260304/New-fragmentome-technology-can-detect-early-liver-fibrosis-and-cirrhosis.aspx","domain":"news-medical.net"}],"translation":{"lang":"cs","id":617,"title":"AI krevní test z Johns Hopkins odhalí tiché onemocnění jater roky před prvními příznaky","url":"https://techtools.cz/tools/news/clanek/617-ai-krevni-test-z-johns-hopkins-odhali-tiche-onemocneni-jater-roky-pred-prvnimi","api_url":"https://techtools.cz/news-api/v1/articles/617?lang=cs"},"content":"Researchers at Johns Hopkins Kimmel Cancer Center have developed an AI-powered liquid biopsy that detects early liver fibrosis and cirrhosis by scanning fragmentation patterns in cell-free DNA circulating in the blood. The test analyzes roughly 40 million DNA fragments across thousands of genomic regions per patient — more data than almost any other liquid biopsy — using machine learning to identify disease-specific signatures.\n\nThe study, published March 4 in Science Translational Medicine, examined samples from 1,576 individuals with liver disease. Current blood tests miss early fibrosis entirely and detect cirrhosis only about 50% of the time. The new fragmentome approach showed significantly higher sensitivity, catching disease at stages when it is still reversible. An estimated 100 million Americans have liver conditions that put them at risk for cirrhosis and liver cancer.\n\nBeyond liver disease, the technology also picked up signals associated with cardiovascular, inflammatory, and neurodegenerative conditions, suggesting it could become a broad screening tool for chronic diseases. The assay remains a prototype and has not yet entered clinical use."}}